Results 21 to 30 of about 29,631 (205)

Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. [PDF]

, 2022
Importance SARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years.
von Meißner, Wolfgang C. G., Strumann, Christoph, Jorczyk, Maximilian, von Poblotzki, Emilie, Drinka, Denisa, Moor, Matthias B., Stuppe, David, Moor, Jeanne, Moor, Matthias B, Toepfner, Nicole, Liss, Melanie, von Meißner, Wolfgang C G, Chao, Cho-Ming, Berner, Reinhard, Püschel, Johannes   +14 more
core   +1 more source

Neutralizing Activity of BNT162b2-Elicited Serum

New England Journal of Medicine, 2021
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first ide...
Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi   +17 more
openaire   +2 more sources

Strength and durability of antibody responses to BNT162b2 and CoronaVac [PDF]

Vaccine, 2022
ABSTRACT We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults
Benjamin J. Cowling, Irene O. L. Wong, Eunice Y. C. Shiu, Amber Y. T. Lai, Samuel M. S. Cheng, Sara Chaothai, Kelvin K. H. Kwan, Mario Martín-Sánchez, Leo L. M. Poon, Dennis K. M. Ip, Gabriel M. Leung, Nancy H. L. Leung, J. S. Malik Peiris   +12 more
openaire   +2 more sources

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination [PDF]

Infectious Diseases and Therapy
Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participants before and ...
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups   +25 more
doaj   +2 more sources

Systems vaccinology of the BNT162b2 mRNA vaccine in humans [PDF]

Nature, 2021
The emergency use authorization of two mRNA vaccines in less than a year from the emergence of SARS-CoV-2 represents a landmark in vaccinology1,2. Yet, how mRNA vaccines stimulate the immune system to elicit protective immune responses is unknown. Here we used a systems vaccinology approach to comprehensively profile the innate and adaptive immune ...
Prabhu S. Arunachalam, Madeleine K. D. Scott, Thomas Hagan, Chunfeng Li, Yupeng Feng, Florian Wimmers, Lilit Grigoryan, Meera Trisal, Venkata Viswanadh Edara, Lilin Lai, Sarah Esther Chang, Allan Feng, Shaurya Dhingra, Mihir Shah, Alexandra S. Lee, Sharon Chinthrajah, Sayantani B. Sindher, Vamsee Mallajosyula, Fei Gao, Natalia Sigal, Sangeeta Kowli, Sheena Gupta, Kathryn Pellegrini, Gregory Tharp, Sofia Maysel-Auslender, Sydney Hamilton, Hadj Aoued, Kevin Hrusovsky, Mark Roskey, Steven E. Bosinger, Holden T. Maecker, Scott D. Boyd, Mark M. Davis, Paul J. Utz, Mehul S. Suthar, Purvesh Khatri, Kari C. Nadeau, Bali Pulendran   +37 more
openaire   +2 more sources

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers

Vaccines, 2023
Assessing immune responses post-SARS-CoV-2 vaccination is crucial for optimizing vaccine strategies. This prospective study aims to evaluate immune responses and breakthrough infection in 235 infection-naïve healthcare workers up to 13–15 months after initial vaccination in two vaccine groups (108 BNT/BNT/BNT and 127 ChAd/ChAd/BNT).
Geon Young Ko, Jihyun Lee, Hyunjoo Bae, Ji Hyeong Ryu, Hye-Sun Park, Hyunhye Kang, Jin Jung, Ae-Ran Choi, Raeseok Lee, Dong-Gun Lee, Eun-Jee Oh   +10 more
openaire   +3 more sources

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination [PDF]

, 2022
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of ...
Salzberger, Bernd, Peterhoff, David, Bauswein, Markus, Hiergeist, Andreas, Schmidt, Barbara, Gessner, André, Bauernfeind, Stilla, Wagner, Ralf, Plentz, Annelie   +8 more
core   +1 more source

Waning Immunity after the BNT162b2 Vaccine in Israel

New England Journal of Medicine, 2021
In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021.
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman, Eric J. Haas, Ron Milo, Sharon Alroy-Preis, Nachman Ash, Amit Huppert   +9 more
openaire   +2 more sources

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination [PDF]

, 2022
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples
Chiara Orlandi, Magnani, Mauro, Marcello Ceccarelli, Eugenio Carlotti, Ceccarelli, Marcello, Daniela Vandini, Carlotti, Eugenio, Orlandi, Chiara, Luca Galluzzi, Gloria Buffi, Barocci, Simone, Anna Casabianca, Galluzzi, Luca, Mauro Magnani, Rocchi, Marco Bruno Luigi, Casabianca, Anna, Aurora Diotallevi, Diotallevi, Aurora, Vandini, Daniela, Simone Barocci, Buffi, Gloria, Marco Bruno Luigi Rocchi   +21 more
core   +1 more source

Myopericarditis following both BNT162b2 and NVX-CoV2373

Allergy, Asthma & Clinical Immunology, 2022
Abstract Background Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population.
Saima Ahmad, Chino Yuson, Adrianna Le, Pravin Hissaria   +3 more
openaire   +3 more sources